Please use this identifier to cite or link to this item:
Title: The Genetic Basis of Moyamoya Disease
Author: Mertens, Robert
Graupera i Garcia-Milà, Mariona
Gerhardt, Holger
Bersano, Anna
Tournier-lasserve, Elisabeth
Mensah, Martin A.
Mundlos, Stefan
Vajkoczy, Peter
Keywords: Malalties cerebrovasculars
Cerebrovascular disease
Issue Date: 16-Sep-2021
Publisher: Springer Science and Business Media LLC
Abstract: Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a "puff of smoke" (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only.
Note: Reproducció del document publicat a:
It is part of: Translational Stroke Research, 2021
Related resource:
ISSN: 1868-601X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Mertens2021_Article_TheGeneticBasisOfMoyamoyaDisea.pdf1.52 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons